Literature DB >> 15172985

Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.

Nebojsa Mirkovic1, Marc A Marti-Renom, Barbara L Weber, Andrej Sali, Alvaro N A Monteiro.   

Abstract

The BRCA1 gene from individuals at risk of breast and ovarian cancers can be screened for the presence of mutations. However, the cancer association of most alleles carrying missense mutations is unknown, thus creating significant problems for genetic counseling. To increase our ability to identify cancer-associated mutations in BRCA1, we set out to use the principles of protein three-dimensional structure as well as the correlation between the cancer-associated mutations and those that abolish transcriptional activation. Thirty-one of 37 missense mutations of known impact on the transcriptional activation function of BRCA1 are readily rationalized in structural terms. Loss-of-function mutations involve nonconservative changes in the core of the BRCA1 C-terminus (BRCT) fold or are localized in a groove that presumably forms a binding site involved in the transcriptional activation by BRCA1; mutations that do not abolish transcriptional activation are either conservative changes in the core or are on the surface outside of the putative binding site. Next, structure-based rules for predicting functional consequences of a given missense mutation were applied to 57 germ-line BRCA1 variants of unknown cancer association. Such a structure-based approach may be helpful in an integrated effort to identify mutations that predispose individuals to cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172985     DOI: 10.1158/0008-5472.CAN-03-3009

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824.

Authors:  Silke Feuerriegel; Claudio U Köser; Davide Baù; Sabine Rüsch-Gerdes; David K Summers; John A C Archer; Marc A Marti-Renom; Stefan Niemann
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2.

Authors:  David E Goldgar; Douglas F Easton; Amie M Deffenbaugh; Alvaro N A Monteiro; Sean V Tavtigian; Fergus J Couch
Journal:  Am J Hum Genet       Date:  2004-08-02       Impact factor: 11.025

3.  Functional hot spots in human ATP-binding cassette transporter nucleotide binding domains.

Authors:  Libusha Kelly; Hisayo Fukushima; Rachel Karchin; Jason M Gow; Leslie W Chinn; Ursula Pieper; Mark R Segal; Deanna L Kroetz; Andrej Sali
Journal:  Protein Sci       Date:  2010-11       Impact factor: 6.725

Review 4.  Functional assays for BRCA1 and BRCA2.

Authors:  Marcelo A Carvalho; Fergus J Couch; Alvaro N A Monteiro
Journal:  Int J Biochem Cell Biol       Date:  2006-08-18       Impact factor: 5.085

5.  Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.

Authors:  Marcelo A Carvalho; Sylvia M Marsillac; Rachel Karchin; Siranoush Manoukian; Scott Grist; Ramona F Swaby; Turan P Urmenyi; Edson Rondinelli; Rosane Silva; Luis Gayol; Lisa Baumbach; Rebecca Sutphen; Jennifer L Pickard-Brzosowicz; Katherine L Nathanson; Andrej Sali; David Goldgar; Fergus J Couch; Paolo Radice; Alvaro N A Monteiro
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

6.  Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.

Authors:  Marc Tischkowitz; Nancy Hamel; Marcelo A Carvalho; Gabriel Birrane; Aditi Soni; Erik H van Beers; Simon A Joosse; Nora Wong; David Novak; Louise A Quenneville; Scott A Grist; Petra M Nederlof; David E Goldgar; Sean V Tavtigian; Alvaro N Monteiro; John A A Ladias; William D Foulkes
Journal:  Eur J Hum Genet       Date:  2008-02-20       Impact factor: 4.246

Review 7.  BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.

Authors:  D M Eccles; G Mitchell; A N A Monteiro; R Schmutzler; F J Couch; A B Spurdle; E B Gómez-García
Journal:  Ann Oncol       Date:  2015-07-07       Impact factor: 32.976

8.  In silico analysis of missense substitutions using sequence-alignment based methods.

Authors:  Sean V Tavtigian; Marc S Greenblatt; Fabienne Lesueur; Graham B Byrnes
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

9.  Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.

Authors:  Marcelo Carvalho; Maria A Pino; Rachel Karchin; Jennifer Beddor; Martha Godinho-Netto; Rafael D Mesquita; Renato S Rodarte; Danielle C Vaz; Viviane A Monteiro; Siranoush Manoukian; Mara Colombo; Carla B Ripamonti; Richard Rosenquist; Graeme Suthers; Ake Borg; Paolo Radice; Scott A Grist; Alvaro N A Monteiro; Blase Billack
Journal:  Mutat Res       Date:  2008-10-17       Impact factor: 2.433

10.  Evidence for a pathogenic role of BRCA1 L1705P and W1837X germ-line mutations.

Authors:  Anna P Sokolenko; Nikita M Volkov; Elena V Preobrazhenskaya; Evgeny N Suspitsin; Aigul R Garifullina; Alexandr V Ivantsov; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Mol Biol Rep       Date:  2016-03-07       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.